iBio, Inc.

iBio, Inc. is a biotechnology startup founded in 2008, based in the United States, with a mission to develop safer and more effective immunotherapies for challenging cancers through their Discovery Platform. The company's slogan "AI-Powered Precision Antibody Therapeutics" highlights their use of artificial intelligence to guide drug discovery, making therapeutic development smarter, more precise, and faster. With a focus on hard-to-drug targets, iBio has $15.00M in Post-IPO Equity investment as of 26 March 2024 from investors including Ikarian Capital, Lynx1 Capital Management, and ADAR1 Capital Management. iBio's approach addresses the essential challenge in developing antibody drugs, which traditionally involves a high degree of randomness and time-consuming, costly methods. The company's nine immuno-oncology candidates in the pipeline aim to target solid tumors, glioblastoma, and head and neck cancers. By utilizing their Discovery Platform, iBio is poised to revolutionize the precision and efficiency of therapeutic development. This approach is expected to yield a higher success rate in bringing potentially life-saving drugs to market, thereby challenging the status quo in drug discovery and development.